Skip to content
Kreastel
Opening soon

paclitaxel

As the list published 4 Feb 2026 has it, binding since 28 Aug 2024. Each entry binds six months after its own publication date (Article 107c(7) of Directive 2001/83/EC).

What the list says

EU reference date
29 Dec 1992
PSUR frequency
5 years
Data lock point
28 Dec 2026
Submission date
28 Mar 2027
Next data lock point
Not stated
Next submission date
Not stated
Products covered
Nationally authorised (NAP)

Are PSURs required for products referred to in Articles 10(1), 10a and 16a of Directive 2001/83/EC?

No — the list does not require PSURs for these products.

The list asks this as one question for Articles 10(1), 10a and 16a together, and does not answer it for Article 14 at all. A PSUR may in any case be required at the request of a competent authority or as a condition of the marketing authorisation.

Notes in the list

Reference to CAP removed on 28/02/2024 PSUR frequency and DLP were updated on 21/09/2022 DLP was updated on 31/07/2019 New CAP authorised on 20/11/2018 PRAC Representative updated on 26/09/2018 Next DLP was updated on 22/09/2016 Lead MS was added on 13/07/2015

Track dates like these for your own products: a sample workspace, read-only, no account needed.

Try the demo

The next three reports

  • Data lock point 28 Dec 2026Submission by 28 Mar 2027
  • Data lock point 28 Dec 2031Submission by 27 Mar 2032
  • Data lock point 28 Dec 2036Submission by 28 Mar 2037

Counted from the data lock point the list gives, on the cycle it states: the submission date is 90 days after the data lock point — 70 days for a cycle of twelve months or less, 90 days for a longer one, as GVP Module VII sets out.

In earlier versions of the list

  • EMA/630645/2012 Rev.164 · published 23 Sept 2026

    paclitaxel — every 5 years, data lock point 28 Dec 2026

  • EMA/630645/2012 Rev.156 · published 4 Feb 2026

    paclitaxel — every 5 years, data lock point 28 Dec 2026

Source: European Medicines Agency, list of EU reference dates and frequency of submission of periodic safety update reports, EMA/630645/2012 Rev.156, published 4 Feb 2026. Open the published file

Kreastel is a planning and oversight aid for pharmacovigilance obligations. It tracks dates like these for a marketing authorisation holder's own products.

Report a discrepancy — if this page and the published file disagree, the file is right and we want to know.

Kreastel